Clinical Trial: A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title:
Brief Summary: The purpose of this study is to evaluate the safety, efficacy, and pharmacokinetics of KPS-0373 in SCD patients (Experience of clinical trials of KPS-0373)
Detailed Summary:
Sponsor: Kissei Pharmaceutical Co., Ltd.
Current Primary Outcome: SARA (Scale for the Assessment and Rating of Ataxia) [ Time Frame: 24 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome: SF-8 (QOL) [ Time Frame: 24 weeks ]
Original Secondary Outcome: Same as current
Information By: Kissei Pharmaceutical Co., Ltd.
Dates:
Date Received: October 22, 2013
Date Started:
Date Completion:
Last Updated: April 15, 2016
Last Verified: April 2016